With recent advances in precision medicine, clinicogenomic data has become increasingly important. In this panel discussion featuring SMEs from leading pharmaceutical, molecular testing, and healthcare companies, we will explore the following themes and topics:

The importance of diverse phenotypic & genotypic profiles

Improving regulatory approval outcomes

Identifying new biomarkers for treatment response

Label expansion by expanding existing treatments to new cohorts or conditions

Using RWE as digital control arms for clinical trials

Who should attend?

  • Translational Research
  • Epidemiology
  • Biomarker Leaders
  • Medical Affair
  • HEOR
  • Clinical Development
  • RWD&A Strategy and Partnership leaders

Click here to find additional details and registration information.


Related Content

Delphi Panels: What Are They Good For?

Delphi Panels: What Are They Good For?

In this webinar, experts will deep dive into Delphi panel methods, their implementation, and pharmaceutical industry insights on the panels' use and outcomes.